Psoriatic arthritis: Latest treatments and their place in therapy

Therapeutic Advances in Chronic Disease

Volumn 6, Issue 4, 2015, Pages 194-203

  Kang, Eun Jin ^a   Kavanaugh, Arthur ^b  

^a Busan Medical Center   (South Korea)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Disease modifying antirheumatic drugs; Immunomodulatory therapies; Psoriatic arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; APREMILAST; BRODALUMAB; CELECOXIB; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; IXEKIZUMAB; JANUS KINASE INHIBITOR; LEFLUNOMIDE; METHOTREXATE; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RITUXIMAB; SALAZOSULFAPYRIDINE; SECUKINUMAB; STAT PROTEIN; TACROLIMUS; TOCILIZUMAB; TOFACITINIB; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB;

CARDIOVASCULAR DISEASE; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE SEVERITY; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; GASTROINTESTINAL TOXICITY; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; HYPERTENSION; MONOTHERAPY; MULTICENTER STUDY (TOPIC); NEPHROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RADIOGRAPHY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT DURATION;

EID: 84930804615     PISSN: 20406223     EISSN: 20406231     Source Type: Journal    
DOI: 10.1177/2040622315582354     Document Type: Review

References (83)

1. Altmeyer M. Kerisit K. Boh E. (2011) Therapeutic hotline. Abatacept: our experience of use in two patients with refractory psoriasis and psoriatic arthritis. Dermatol Ther 24: 287–290.
2. Antoni C. Kavanaugh A. van der Heijde D. Beutler A. Keenan G. Zhou B. et al. (2008) Two-year efficacy and safety of Infliximab treatment in patients with active psoriatic arthritis: findings of the infliximab multinational psoriatic arthritis controlled trial (impact). J Rheumatol 35: 869–876.
3. Antoni C. Krueger G. de Vlam K. Birbara C. Beutler A. Guzzo C. et al. (2005) Infliximab improves signs and symptoms of psoriatic arthritis: results of the impact 2 trial. Ann Rheum Dis 64: 1150–1157.
4. Asiri A. Thavaneswaran A. Kalman-Lamb G. Chandran V. Gladman D. (2014) The effectiveness of leflunomide in psoriatic arthritis. Clin Exp Rheumatol 32: 728–731.
5. Atteno M. Peluso R. Costa L. Padula S. Iervolino S. Caso F. et al. (2010) Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying Antirheumatic drugs. Clin Rheumatol 29: 399–403.
6. Behrens F. Canete J. Olivieri I. van Kuijk A. McHugh N. Combe B. (2014) Tumor necrosis factor inhibitor monotherapy versus combination with MTX in the treatment of PsA: a systemic review of the literature. Rheumatology [Epub ahead of print].
7. Behrens F. Finkenwirth C. Pavelka K. Stolfa J. Sipek-Dolnicar A. Thaci D. et al. (2013) Leflunomide in psoriatic arthritis: results from a large European prospective observational study. Arthritis Care Res (Hoboken) 65: 464–470.
8. Ceponis A. Kavanaugh A. (2010) Use of methotrexate in patients with psoriatic arthritis. Clin Exp Rheumatol 28: S132–S137.
9. Clegg D. Reda D. Abdellatif M. (1999) Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a department of veterans affairs cooperative study. Arthritis Rheum 42: 2325–2329.
10. Costa L. Caso F. Cantarini L. Del Puente A. Scarpa R. Atteno M. (2014) Efficacy of tocilizumab in a patient with refractory psoriatic arthritis. Clin Rheumatol 33: 1355–1357.
11. Curtis J. Beukelman T. Onofrei A. Cassell S. Greenberg J. Kavanaugh A. et al. (2010) Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and / or leflunomide. Ann Rheum Dis 69: 43–47.
12. Cutolo M. Myerson G. Fleischmann R. Liote F. Diaz-Gonzalez F. van den Bosch F. et al. (2013) Long-term (52-week) results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis (PALACE2). Arthritis Rheum 65: S346.
13. D'Angelo S. Palazzi C. Olivieri I. (2012) Psoriatic arthritis: treatment strategies using biologic agents. Reumatismo 64: 113–121.
14. Edwards C. Blanco F. Crowley J. Hu C. Stevens R. Birbara C. et al. (2013) Long-term (52-week) results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement. Arthritis Rheum 65: S132.
15. Eriksen K. Lovato P. Skov L. Krejsgaard T. Kaltoft K. Geisler C. et al. (2005) Increased sensitivity to interferon-alpha in psoriatic T cells. J invest Dermatol 125: 936–944.
16. Fagerli K. Lie E. van der Heijde D. Heiberg M. Kalstad S. Rodevand E. et al. (2013) Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study. Ann Rheum Dis 72: 1840–1844.
17. Fenix-Caballero S. Alegre-Del Rey E. Castano-Lara R. Puigventos-Latorre F. Borrero-Rubio J. Lopez-Vallejo J. (2013) Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis. J Clin Pharm Ther 38: 286–293.
18. Fiocco U. Accordi B. Martini V. Oliviero F. Facco M. Cabrelle A. et al. (2014) JAK/STAT/PKCδ molecular pathway in synovial fluid T lymphocytes reflect the in vivo T helper-17 expansion in psoriatic arthritis. Immunol Res 58: 61–69.
19. Fiocco U. Sfriso P. Oliviero F. Lunardi F. Calabrese F. Scagliori E. et al. (2013) Blockade of intra-articular TNF in peripheral spondyloarthritis: its relevance to clinical scores, quantitative imaging and synovial fluid and synovial tissue biomarkers. Joint Bone Spine 80: 165–170.
20. Fraser A. van Kuijk A. Westhovens R. Karim Z. Wakefield R. Gerards A. et al. (2005) A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis 64: 859–864.
21. Ghoreschi K. Laurence A. O'Shea J. (2009) Janus kinases in immune cell signaling. Immunol Rev 228: 273–287.
22. Gladman D. Antoni C. Mease P. Clegg D. Nash P. (2005) Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 64(Suppl. 2): ii14–ii17.
23. Gladman D. Mease P. Ritchlin C. Choy E. Sharp J. Ory P. et al. (2007) Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum 56: 476–488.
24. Glintborg B. Ostergaard M. Krogh N. Andersen M. Tarp U. Loft A. et al. (2013) Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor alpha inhibitor therapy: results from the Danish Nationwide Danbio Registry. Arthritis Rheum 65: 1213–1223.
25. Gossec L. Smolen J. Gaujoux-Viala C. Ash Z. Marzo-Ortega H. van der Heijde D. et al. (2012) European league against rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 71: 4–12.
26. Gottlieb A. Mease P. McInnes I. Kirkham B. Kavanaugh A. Rahman P. et al. (2014) Secukinumab, a human anti-interleukin-17A monoclonal antibody, significantly reduces psoriasis burden in patients with psoriatic arthritis: results from a phase 3 randomized controlled trial. Arthritis (ACR meeting Abstract) 66: S233.
27. Gupta A. Grober J. Hamilton T. Ellis C. Siegel M. Voorhees J. et al. (1995) Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial. J Rheumatol 22: 894–898.
28. Hald A. Andres R. Salskov-Iversen M. Kjellerup R. Iversen L. Johansen C. (2013) STAT 1 expression and activation is increased in lesional psoriatic skin. Br J Dermatol 168: 302–310.
29. Hughes M. Chinoy H. (2013) Successful use of tocilizumab in a patient with psoriatic arthritis. Rheumatology (Oxford) 52: 1728–1729.
30. Huynh D. Kavanaugh A. (2015) Psoriatic arthritis: current therapy and future approaches. Rheumatology (oxford) 54: 20–28.
31. Jimenez-Boj E. Stamm T. Sadlonova M. Rovensky J. Raffayova H. Leeb B. et al. (2012) Rituximab in psoriatic arthritis: an exploratory evaluation. Ann Rheum Dis 71: 1868–1871.
32. Kaltwasser J. (2007) Leflunomide in psoriatic arthritis. Autoimmun Rev 6: 511–514.
33. Karanikolas G. Koukli E. Katsalira A. Arida A. Petrou D. Komninou E. et al. (2011) Adalimumab or cyclosporine as monotherapy and in combination in severe psoriatic arthritis: results from a prospective 12-month nonrandomized unblinded clinical trial. J Rheumatol 38: 2466–2474.
34. Kavanaugh A. Krueger G. Beutler A. Guzzo C. Zhou B. Dooley L. et al. (2007) Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the impact 2 trial. Ann Rheum Dis 66: 498–505.
35. Kavanaugh A. McInnes I. Mease P. Krueger G. Gladman D. van der Heijde D. et al. (2013) Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled Go-Reveal Study. Ann Rheum Dis 72: 1777–1785.
36. Kavanaugh A. McInnes I. Mease P. Krueger G. Gladman D. van der Heijde D. et al. (2014 a) Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the Go-Reveal Study). Ann Rheum Dis 73: 1689–1694.
37. Kavanaugh A. McInnes I. Mease P. Krueger G. Gladman D. Gomez-Reino J. et al. (2009) Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 60: 976–986.
38. Kavanaugh A. Mease P. Gomez-Reino J. Adebajo A. Wollenhaupt J. Gladman D. et al. (2014 b) Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis 73: 1020–1026.
39. Kavanaugh A. Ritchlin C. Rahman P. Puig L. Gottlieb A. Li S. et al. (2014 c) Ustekinumab, an anti-Il-12/23 P 40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, placebo-controlled PSUMMIT-1 and PUMMIT-2 trials. Ann Rheum Dis 73: 1000–1006.
40. Kavanaugh A. van der Heijde D. McInnes I. Mease P. Krueger G. Gladman D. et al. (2012) Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum 64: 2504–2517.
41. Kingsley G. Kowalczyk A. Taylor H. Ibrahim F. Packham J. McHugh N. et al. (2012) A randomized placebo-controlled trial of Methotrexate in psoriatic arthritis. Rheumatology (Oxford) 51: 1368–1377.
42. Kivitz A. Espinoza L. Sherrer Y. Liu-Dumaw M. West C. (2007) A comparison of the efficacy and safety of celecoxib 200 mg and celecoxib 400 mg once daily in treating the signs and symptoms of psoriatic arthritis. Semin Arthritis Rheum 37: 164–173.
43. Kontzias A. Kotlyar A. Laurence A. Changelian P. O'Shea J. (2012) Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease. Curr Opin Pharmacol 12: 464–470.
44. Leonardi C. Matheson R. Zachariae C. Cameron G. Li L. Edson-Heredia E. et al. (2012) Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 366: 1190–1199.
45. McHugh N. Balachrishnan C. Jones S. (2003) Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology (Oxford) 42: 778–783.
46. McInnes I. Kavanaugh A. Gottlieb A. Puig L. Rahman P. Ritchlin C. et al. (2013) Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 382: 780–789.
47. McInnes I. Sieper J. Braun J. Emery P. van der Heijde D. Isaacs J. et al. (2014) Efficacy and safety of secukinumab, a fully human anti-interleukin-17a monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis 73: 349–356.
48. Mease P. (2012) Spondyloarthritis: is methotrexate effective in psoriatic arthritis? Nat Rev Rheumatol 8: 251–252.
49. Mease P. Fleischmann R. Deodhar A. Wollenhaupt J. Khraishi M. Kielar D. et al. (2014 a) Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind randomised placebo-controlled study (RAPID-PSA). Ann Rheum Dis 73: 48–55.
50. Mease P. Genovese M. Gladstein G. Kivitz A. Ritchlin C. Tak P. et al. (2011) Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. Arthritis Rheum 63: 939–948.
51. Mease P. Genovese M. Greenwald M. Ritchlin C. Beaulieu A. Deodhar A. et al. (2014 b) Brodalumab, an anti-Il17ra monoclonal antibody, in psoriatic arthritis. N Engl J Med 370: 2295–2306.
52. Mease P. Gladman D. Ritchlin C. Ruderman E. Steinfeld S. Choy E. et al. (2005) Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52: 3279–3289.
53. Mease P. Goffe B. Metz J. Vanderstoep A. Finck B. Burge D. (2000) Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 356: 385–390.
54. Mease P. Kivitz A. Burch F. Siegel E. Cohen S. Ory P. et al. (2004) Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 50: 2264–2272.
55. Mease P. Kivitz A. Burch F. Siegel E. Cohen S. Ory P. et al. (2006) Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 33: 712–721.
56. Mease P. McInnes I. Kirkham B. Kavanaugh A. Rahman P. van der Heijde D. et al. (2014 c) Secukinumab, a human anti-interleukin-17A monoclonal antibody, improves active psoriatic arthritis and inhibits radiographic progression: efficacy and safety data from a phase 3 randomized, multicenter, double-blind, placebo-controlled study. ACR Meeting, 14–19 November, Boston, MA.
57. Mease P. Ory P. Sharp J. Ritchlin C. van Den Bosch F. Wellborne F. et al. (2009) Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the adalimumab effectiveness in psoriatic arthritis trial (ADEPT). Ann Rheum Dis 68: 702–709.
58. Mrowietz U. Domm S. (2013) Systemic steroids in the treatment of psoriasis: what is fact, what is fiction? J Eur Acad Dermatol Venereol 27: 1022–1025.
59. Nash P. Thaci D. Behrens F. Falk F. Kaltwasser J. (2006) Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study. Dermatology 212: 238–249.
60. Ogata A. Umegaki N. Katayama I. Kumanogoh A. Tanaka T. (2012) Psoriatic arthritis in two patients with an inadequate response to treatment with tocilizumab. Joint Bone Spine 79: 85–87.
61. Olivieri I. D'Angelo S. Palazzi C. Padula A. (2014) Advances in the management of psoriatic arthritis. Nat Rev Rheumatol 10: 531–542.
62. Palfreeman A. McNamee K. McCann F. (2013) New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast. Drug Des Devel Ther 7: 201–210.
63. Papp K. Langley R. Sigurgeirsson B. Abe M. Baker D. Konno P. et al. (2013) Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol 168: 412–421.
64. Papp K. Leonardi C. Menter A. Ortonne J. Krueger J. Kricorian G. et al. (2012) Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 366: 1181–1189.
65. Ports W. Khan S. Lan S. Lamba M. Bolduc C. Bissonnette R. et al. (2013) A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol 169: 137–145.
66. Racz E. Prens E. Kurek D. Kant M. de Ridder D. Mourits S. et al. (2011) Effective treatment of psoriasis with narrow-band UVB photo therapy is linked to suppression of the IFN and Th 17 pathways. J Invest Dermatol 131: 1547–1558.
67. Rahman P. Gladman D.D. Cook R.J. Zhou Y. Young G. (1998) The use of sulfasalazine in psoriatic arthritis: a clinical experience. J Rheumatol 25:1957–1961.
68. Ritchlin C. Kavanaugh A. Gladman D. Mease P. Helliwell P. Boehncke W. et al. (2009) Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 68: 1387–1394.
69. Ritchlin C. Rahman P. Kavanaugh A. McInnes I. Puig L. Li S. et al. (2014) Efficacy and safety of the anti-Il-12/23 P 40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 73: 990–999.
70. Sakellariou G. Sayegh F. Anastasilakis A. Kapetanos G. (2013) Leflunomide addition in patients with articular manifestations of psoriatic arthritis resistant to methotrexate. Rheumatol Int 33: 2917–2920.
71. Salvarani C. Macchioni P. Olivieri I. Marchesoni A. Cutolo M. Ferraccioli G. et al. (2001) A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis. J Rheumatol 28: 2274–2282.
72. Sarzi-Puttini P. Santandrea S. Boccassini L. Panni B. Caruso I. (2001) The role of NSAIDs in psoriatic arthritis: evidence from a controlled study with nimesulide. Clin Exp Rheumatol 19: S17–S20.
73. Schafer P. (2012) Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol 83: 1583–1590.
74. Schett G. Wollenhaupt J. Papp K. Joos R. Rodrigues J. Vessey A. et al. (2012) Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 64: 3156–3167.
75. Sterry W. Ortonne J. Kirkham B. Brocq O. Robertson D. Pedersen R. et al. (2010) Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ 340: c147.
76. Thorlund K. Druyts E. Avina-Zubieta J. Mills E. (2012) Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis. Biologics 6: 417–427.
77. Ursini F. Naty S. Russo E. Grembiale R. (2013) Abatacept in psoriatic arthritis: case report and short review. J Pharmacol Pharmacother 4: S29–S32.
78. van Kuijk A. de Groot M. Stapel S. Dijkmans B. Wolbink G. Tak P. (2010) Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis. Ann Rheum Dis 69: 624–625.
79. Veale D. (2011) New therapies and new goals for psoriatic arthritis. Arthritis Rheum 63: 874–876.
80. Veale D. (2013) Psoriatic arthritis: recent progress in pathophysiology and drug development. Arthritis Res Ther 15: 224.
81. Wells A. Edwards C. Adebajo A. Kivitz A. Bird P. Shah K. et al. (2013) Apremilast in the treatment of DMARD-naïve psoriatic arthritis patients: results of a phase 3 randomized controlled trial (PALACE4). Arthritis Rheum 65: S3320–S3321.
82. Wendling D. Dougados M. Berenbaum F. Brocq O. Schaeverbeke T. Mazieres B. et al. (2012) Rituximab treatment for spondyloarthritis. a nationwide series: data from the Air Registry of the French Society of Rheumatology. J Rheumatol 39: 2327–2331.
83. Zisapel M. Zisman D. Madar-Balakirski N. Arad U. Padova H. Martz H. et al. (2015) Prevalence of TNF-α blocker immunogenecity in psoriatic arthritis. J Rheumatol 42: 73–78.